{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:13Z","timestamp":1791357553064,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T00:00:00Z","timestamp":1308528000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-244x-11-101","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:46:25Z","timestamp":1308624385000},"source":"Crossref","is-referenced-by-count":57,"title":["Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials"],"prefix":"10.1186","volume":"11","author":[{"given":"Armin","family":"Szegedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"van Willigenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari R","family":"Nations","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mackle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Panagides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,20]]},"reference":[{"key":"852_CR1","unstructured":"Diagnostic and Statistical Manual of Mental Disorders. Text Revision. 2000, Arlington, VA: American Psychiatric Association, Fourth"},{"issue":"1","key":"852_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11920-008-0012-7","volume":"10","author":"RS McIntyre","year":"2008","unstructured":"McIntyre RS, Muzina DJ, Kemp DE, Blank D, Woldeyohannes HO, Lofchy J, Soczynska JK, Banik S, Konarski JZ: Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep. 2008, 10 (1): 66-72. 10.1007\/s11920-008-0012-7.","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"852_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"LL Judd","year":"2002","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002, 59 (6): 530-537. 10.1001\/archpsyc.59.6.530.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"852_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.4088\/JCP.v68n0811","volume":"68","author":"GE Simon","year":"2007","unstructured":"Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J: Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007, 68 (8): 1237-1245. 10.4088\/JCP.v68n0811.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"852_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/00023210-200317070-00003","volume":"17","author":"L Tondo","year":"2003","unstructured":"Tondo L, Isacsson G, Baldessarini R: Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003, 17 (7): 491-511. 10.2165\/00023210-200317070-00003.","journal-title":"CNS Drugs"},{"issue":"3","key":"852_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/10673221003747955","volume":"18","author":"RJ Baldessarini","year":"2010","unstructured":"Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL: Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010, 18 (3): 143-157. 10.3109\/10673221003747955.","journal-title":"Harv Rev Psychiatry"},{"key":"852_CR7","unstructured":"The World Health Report 2001 - Mental Health: New Understanding, New Hope. [ http:\/\/www.who.int\/whr\/2001\/en\/whr01_en.pdf ]"},{"key":"852_CR8","unstructured":"Seroquel\u00ae (quetiapine fumarate). 2009, Wilmington, DE: AstraZeneca"},{"key":"852_CR9","unstructured":"Symbyax\u00ae (olanzapine and fluoxetine hydrochloride). 2010, Indianapolis, IN: Eli Lilly and Company"},{"issue":"1","key":"852_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009, 23 (1): 65-73.","journal-title":"J Psychopharmacol"},{"key":"852_CR11","unstructured":"Saphris\u00ae (asenapine sublingual tablets). 2010, Whitehouse Station, NJ: Schering Corporation, a subsidiary of Merck & Co., Inc"},{"key":"852_CR12","unstructured":"European Medicines Agency. Sycrest\u00ae (asenapine). [ http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001177\/human_med_001379.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true ]"},{"key":"852_CR13","volume-title":"J Psychopharmacol (Oxf)","author":"HM Marston","year":"2010","unstructured":"Marston HM, Martin FDC, Papp M, Gold LH, Wong EHF, Shahid M: Attenuation of chronic mild stress-induced \"anhedonia\" by asenapine is not associated with a \"hedonic\" profile in intracranial self-stimulation. J Psychopharmacol (Oxf). 2010,"},{"issue":"7","key":"852_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009, 11 (7): 673-686. 10.1111\/j.1399-5618.2009.00748.x.","journal-title":"Bipolar Disord"},{"issue":"1-2","key":"852_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","volume":"122","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010, 122 (1-2): 27-38. 10.1016\/j.jad.2009.12.028.","journal-title":"J Affect Disord"},{"issue":"8","key":"852_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009, 11 (8): 815-826. 10.1111\/j.1399-5618.2009.00749.x.","journal-title":"Bipolar Disord"},{"issue":"3","key":"852_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","volume":"126","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek T, Panagides J: Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010, 126 (3): 358-365. 10.1016\/j.jad.2010.04.005.","journal-title":"J Affect Disord"},{"issue":"1-3","key":"852_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2004.01.036","volume":"488","author":"M Giorgetti","year":"2004","unstructured":"Giorgetti M, Tecott LH: Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol. 2004, 488 (1-3): 1-9. 10.1016\/j.ejphar.2004.01.036.","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 8","key":"852_CR19","first-page":"30","volume":"66","author":"P Blier","year":"2005","unstructured":"Blier P, Szabo ST: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005, 66 (Suppl 8): 30-40.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"852_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00213-008-1456-5","volume":"204","author":"O Franberg","year":"2009","unstructured":"Franberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TH: Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl). 2009, 204 (2): 251-264. 10.1007\/s00213-008-1456-5.","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"852_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003, 60 (11): 1079-1088. 10.1001\/archpsyc.60.11.1079.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"852_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005, 162 (7): 1351-1360. 10.1176\/appi.ajp.162.7.1351.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"852_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006, 26 (6): 600-609. 10.1097\/01.jcp.0000248603.76231.b7.","journal-title":"J Clin Psychopharmacol"},{"key":"852_CR24","unstructured":"Abilify\u00ae (aripiprazole). 2006, Princeton, NJ: Bristol-Myers Squibb Company"},{"issue":"1","key":"852_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","volume":"28","author":"ME Thase","year":"2008","unstructured":"Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R: Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008, 28 (1): 13-20. 10.1097\/jcp.0b013e3181618eb4.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"852_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1176\/appi.ajp.163.2.210","volume":"163","author":"AA Nierenberg","year":"2006","unstructured":"Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006, 163 (2): 210-216. 10.1176\/appi.ajp.163.2.210.","journal-title":"Am J Psychiatry"},{"issue":"1-3","key":"852_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jad.2009.01.022","volume":"118","author":"MR Liebowitz","year":"2009","unstructured":"Liebowitz MR, Salman E, Mech A, Dunner D, Johnson AE, Akhtar J, Pratap R: Ziprasidone monotherapy in bipolar II depression: an open trial. J Affect Disord. 2009, 118 (1-3): 205-208. 10.1016\/j.jad.2009.01.022.","journal-title":"J Affect Disord"},{"issue":"1-2","key":"852_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jad.2009.06.023","volume":"122","author":"S Stahl","year":"2010","unstructured":"Stahl S, Lombardo I, Loebel A, Mandel FS: Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord. 2010, 122 (1-2): 39-45. 10.1016\/j.jad.2009.06.023.","journal-title":"J Affect Disord"},{"issue":"2","key":"852_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/15622970903555881","volume":"11","author":"H Grunze","year":"2010","unstructured":"Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010, 11 (2): 81-109. 10.3109\/15622970903555881.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"852_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1017\/S1461145709990344","volume":"13","author":"N Cruz","year":"2010","unstructured":"Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E: Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010, 13 (1): 5-14. 10.1017\/S1461145709990344.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"852_CR31","first-page":"1320","volume":"154","author":"N Mittmann","year":"1997","unstructured":"Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH: Montgomery-Asberg severity gradations. Am J Psychiatry. 1997, 154 (9): 1320-1321.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"852_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","volume":"73","author":"MK Spearing","year":"1997","unstructured":"Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997, 73 (3): 159-171. 10.1016\/S0165-1781(97)00123-6.","journal-title":"Psychiatry Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-11-101\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T05:53:17Z","timestamp":1468129997000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-11-101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-11-101","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,20]]},"article-number":"101"}}